Form 4: Edgewise Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, Inc., sold 5,100 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 5,781 Common Stock on August 12, 2026; holds 29,426 after (Direct).
- Option exercise/conversion: acquired 7,500 Common Stock on August 12, 2026; holds 36,926 after (Direct).
- Open-market sale: disposed of 2,171 Common Stock at $43.79 ($95,075) on August 12, 2026; holds 34,755 after (Direct).
- Open-market sale: disposed of 304 Common Stock at $44.50 ($13,529) on August 12, 2026; holds 34,451 after (Direct).
- Open-market sale: disposed of 150 Common Stock at $44.44 ($6,666) on August 12, 2026; holds 34,301 after (Direct).
- Open-market sale: disposed of 2,475 Common Stock at $43.70 ($108,154) on August 12, 2026; holds 31,826 after (Direct).
- Option exercise/conversion: disposed of 5,781 Restricted Stock Units on August 12, 2026; holds 11,563 after (Direct).
- Option exercise/conversion: disposed of 7,500 Restricted Stock Units on August 12, 2026; holds 22,500 after (Direct).
- Grant/award: acquired 50,000 Restricted Stock Units on August 12, 2026; holds 50,000 after (Direct).
- Grant/award: acquired 100,000 Stock Option (Right to Buy) on August 12, 2026; holds 100,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $223,424 of stock on the open market.
Insider Transactions
Behrad Derakhshan — Officer (Chief Business Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 5,781 | — | — | 29,426 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 7,500 | — | — | 36,926 |
| 2026-08-12 | Open-market sale | Common Stock | 2,171 | $44 | $95.1K | 34,755 |
| 2026-08-12 | Open-market sale | Common Stock | 304 | $45 | $13.5K | 34,451 |
| 2026-08-12 | Open-market sale | Common Stock | 150 | $44 | $6.7K | 34,301 |
| 2026-08-12 | Open-market sale | Common Stock | 2,475 | $44 | $108.2K | 31,826 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 5,781 | — | — | 11,563 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 7,500 | — | — | 22,500 |
| 2026-08-12 | Grant/award | Restricted Stock Units | 50,000 | — | — | 50,000 |
| 2026-08-12 | Grant/award | Stock Option (Right to Buy) | 100,000 | — | — | 100,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (5,781 shares) |
| 2026-08-12 | Option exercise/conversion (7,500 shares) |
| 2026-08-12 | Open-market sale (2,171 shares) |
| 2026-08-12 | Open-market sale (304 shares) |
| 2026-08-12 | Open-market sale (150 shares) |
| 2026-08-12 | Open-market sale (2,475 shares) |
| 2026-08-12 | Option exercise/conversion (5,781 shares) |
| 2026-08-12 | Option exercise/conversion (7,500 shares) |
| 2026-08-12 | Grant/award (50,000 shares) |
| 2026-08-12 | Grant/award (100,000 shares) |
Keywords
insider transaction, Form 4, EWTX, Edgewise Therapeutics, Inc., bearish, Behrad Derakhshan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.